Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Irritable Bowel Syndrome | Research

Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study

Authors: Alireza Olyaiee, Abbas Yadegar, Elnaz Sadat Mirsamadi, Amir Sadeghi, Hamed Mirjalali

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) tract disorder. Although the main reason for IBS is not clear, the interaction between intestinal microorganisms and the gut barrier seems to play an important role in pathogenesis of IBS. The current study aimed to investigate the effect of Blastocystis on the gut microbiota profile and the circulation levels of microRNA (mir)-16 of IBS patients compared to healthy subjects. Stool and blood samples were collected from 80 participants including 40 samples from each IBS and healthy group. Upon DNA extraction from stool samples, barcoding region and quantitative real-time PCR were analyzed to investigate Blastocystis and the microbiota profile, respectively. RNA was extracted from serum samples of included subjects and the expression of mir-16 was evaluated using stem-loop protocol and qreal-time PCR. Significant changes between IBS patients and healthy controls was observed in Firmicutes, Actinobacteria, Faecalibacterium, and Alistipes. In IBS patients, the relative abundance of Bifidobacteria was directly correlated with the presence of Blastocystis, while Alistipes was decreased with Blastocystis. Lactobacillus was significantly increased in Blastocystis carriers. In healthy subjects, the relative abundance of Bifidobacteria was decreased, but Alistipes was increased in Blastocystis carriers. The changes in the Firmicutes/Bacteroidetes ratio was not significant in different groups. The relative expression of mir-16 in Blastocystis-negative IBS patients and healthy carriers was significantly overexpressed compared to control group. The presence of Blastocystis, decreased the relative expression of mir-16 in IBS patients compared to Blastocystis-negative IBS patients. The present study revealed that Blastocystis has the ability to change the abundance of some phyla/genera of bacteria in IBS and healthy subjects. Moreover, Blastocystis seems to  modulate the relative expression of microRNAs  to control the gut atmosphere, apply its pathogenicity, and provide a favor niche for its colonization.
Literature
1.
Olyaiee A, Sadeghi A, Yadegar A, Mirsamadi ES, Mirjalali H. Gut microbiota shifting in irritable bowel syndrome: the mysterious role of Blastocystis sp. Front Med (Lausanne). 2022;9: 890127.PubMedCrossRef
2.
Mei L, Zhou J, Su Y, Mao K, Wu J, Zhu C, He L, Cui Y. Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol. 2021;21:105.PubMedPubMedCentralCrossRef
3.
Johnsen PH, Hilpüsch F, Valle PC, Goll R. The effect of fecal microbiota transplantation on IBS related quality of life and fatigue in moderate to severe non-constipated irritable bowel: Secondary endpoints of a double blind, randomized, placebo-controlled trial. EBioMedicine. 2020;51: 102562.PubMedCrossRef
4.
Nagel R, Traub RJ, Allcock RJ, Kwan MM, Bielefeldt-Ohmann H. Comparison of faecal microbiota in Blastocystis-positive and Blastocystis-negative irritable bowel syndrome patients. Microbiome. 2016;4:47.PubMedPubMedCentralCrossRef
5.
Dale HF, Lied GA. Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives. Turk J Med Sci. 2020;50:1632–41.PubMedCrossRef
6.
Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, Huang T, Ning Z, Zhai L, Zhong LL, et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020;130:438–50.PubMedCrossRef
7.
Gasbarrini A, Lauritano EC, Garcovich M, Sparano L, Gasbarrini G. New insights into the pathophysiology of IBS: intestinal microflora, gas production and gut motility. Eur Rev Med Pharmacol Sci. 2008;12(Suppl 1):111–7.PubMed
8.
Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141:1792–801.PubMedCrossRef
9.
Shankar V, Reo NV, Paliy O. Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome. Microbiome. 2015;3:73.PubMedPubMedCentralCrossRef
10.
11.
Nieves-Ramírez M, Partida-Rodríguez O, Laforest-Lapointe I, Reynolds L, Brown E, Valdez-Salazar A, Morán-Silva P, Rojas-Velázquez L, Morien E, Parfrey L. Asymptomatic intestinal colonization with protist Blastocystis is strongly associated with distinct microbiome ecological patterns. Msystems. 2018;3:e00007-00018.PubMedPubMedCentralCrossRef
12.
Nemati S, Zali MR, Johnson P, Mirjalali H, Karanis P. Molecular prevalence and subtype distribution of Blastocystis sp. in Asia and in Australia. J Water Health. 2021;19:687–704.PubMedCrossRef
13.
Cifre S, Gozalbo M, Ortiz V, Soriano JM, Merino JF, Trelis M. Blastocystis subtypes and their association with Irritable Bowel Syndrome. Med Hypotheses. 2018;116:4–9.PubMedCrossRef
14.
Dogruman-Al F, Simsek Z, Boorom K, Ekici E, Sahin M, Tuncer C, Kustimur S, Altinbas A. Comparison of methods for detection of Blastocystis infection in routinely submitted stool samples, and also in IBS/IBD Patients in Ankara. Turkey PLoS One. 2010;5: e15484.PubMedCrossRef
15.
Beghini F, Pasolli E, Truong TD, Putignani L, Cacciò SM, Segata N. Large-scale comparative metagenomics of Blastocystis, a common member of the human gut microbiome. ISME J. 2017;11:2848–63.PubMedPubMedCentralCrossRef
16.
Asnicar F, Berry SE, Valdes AM, Nguyen LH, Piccinno G, Drew DA, Leeming E, Gibson R, Le Roy C, Khatib HA. Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals. Nat Med. 2021;27:321–32.PubMedPubMedCentralCrossRef
17.
Karamati SA, Mirjalali H, Niyyati M, Yadegar A, Asadzadeh Aghdaei H, Haghighi A, Seyyed Tabaei SJ. Association of Blastocystis ST6 with higher protease activity among symptomatic subjects. BMC Microbiol. 2021;21:285.PubMedPubMedCentralCrossRef
18.
Mirza H, Wu Z, Teo JD, Tan KS. Statin pleiotropy prevents rho kinase-mediated intestinal epithelial barrier compromise induced by Blastocystis cysteine proteases. Cell Microbiol. 2012;14:1474–84.PubMedCrossRef
19.
Mohammad Rahimi H, Yadegar A, Asadzadeh Aghdaei H, Mirjalali H, Zali MR. Modulation of microRNAs and claudin-7 in Caco-2 cell line treated with Blastocystis sp., subtype 3 soluble total antigen. BMC Microbiol. 2022;22:111.PubMedPubMedCentralCrossRef
20.
21.
Martínez C, Rodiño-Janeiro BK, Lobo B, Stanifer ML, Klaus B, Granzow M, González-Castro AM, Salvo-Romero E, Alonso-Cotoner C, Pigrau M. miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea. Gut. 2017;66:1537–8.PubMedCrossRef
22.
Norouzi M, Pirestani M, Arefian E, Dalimi A, Sadraei J, Mirjalali H. Exosomes secreted by Blastocystis subtypes affect the expression of proinflammatory and anti-inflammatory cytokines (TNFα, IL-6, IL-10, IL-4). Front Med (Lausanne). 2022;9: 940332.PubMedCrossRef
23.
Gholam-Mostafaei FS, Azimirad M, Naseri K, Nabavi-Rad A, Asadzadeh Aghdaei H, Shahrokh S, Ebrahimi Daryani N, Yadegar A, Zali MR. Intestinal microbiota changes pre-and post-fecal microbiota transplantation for treatment of recurrent Clostridioides difficile infection among Iranian patients with concurrent inflammatory bowel disease. Front Microbiol. 2023;14:499.CrossRef
24.
De Gregoris TB, Aldred N, Clare AS, Burgess JG. Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa. J Microbiol Method. 2011;86:351–6.CrossRef
25.
Moszak M, Szulińska M, Bogdański P. You are what you eat—the relationship between diet, microbiota, and metabolic disorders—a review. Nutrients. 2020;12:1096.PubMedPubMedCentralCrossRef
26.
27.
Hermann-Bank ML, Skovgaard K, Stockmarr A, Larsen N, Mølbak L. The gut microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity. BMC Genomic. 2013;14:1–14.CrossRef
28.
Springham N, Robert G. Experience based co-design reduces formal complaints on an acute mental health ward. BMJ Open Qual. 2015;4(u209153): w203970.
29.
Keshavarz Azizi Raftar S, Ashrafian F, Yadegar A, Lari A, Moradi HR, Shahriary A, Azimirad M, Alavifard H, Mohsenifar Z, Davari M. The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD/CCl4-induced liver injury. Microbiol Spect. 2021;9:e00484-e1421.CrossRef
30.
Wang I-K, Lai H-C, Yu C-J, Liang C-C, Chang C-T, Kuo H-L, Yang Y-F, Lin C-C, Lin H-H, Liu Y-L. Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl Environ Microbiol. 2012;78:1107–12.PubMedPubMedCentralCrossRef
31.
Quigley EM. Gut bacteria in health and disease. Gastroenterol Hepatol. 2013;9:560.
32.
Vigsnæs LK, Brynskov J, Steenholdt C, Wilcks A, Licht TR. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Beneficial Microb. 2012;3:287–97.CrossRef
33.
Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111-123.e118.PubMedCrossRef
34.
Zhuang X, Tian Z, Li L, Zeng Z, Chen M, Xiong L. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol. 2018;9:1600.PubMedPubMedCentralCrossRef
35.
Deng L, Wojciech L, Gascoigne NR, Peng G, Tan KS. New insights into the interactions between Blastocystis, the gut microbiota, and host immunity. PLoS Pathog. 2021;17: e1009253.PubMedPubMedCentralCrossRef
36.
Kim MJ, Lee YJ, Kim TJ, Won EJ. Gut microbiome profiles in colonizations with the enteric protozoa Blastocystis in Korean populations. Microorganisms. 2021;10:34.PubMedPubMedCentralCrossRef
37.
Stensvold CR, Sørland BA, Berg R, Andersen LO, van der Giezen M, Bowtell JL, El-Badry AA, Belkessa S, Kurt Ö, Nielsen HV. Stool microbiota diversity analysis of Blastocystis-positive and Blastocystis-negative individuals. Microorganisms. 2022;10:326.PubMedPubMedCentralCrossRef
38.
Olivo-Diaz A, Romero-Valdovinos M, Gudino-Ramirez A, Reyes-Gordillo J, Jimenez-Gonzalez DE, Ramirez-Miranda ME, Martinez-Flores WA, Martinez-Hernandez F, Flisser A, Maravilla P. Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis. Parasitol Res. 2012;111:487–91.PubMedCrossRef
39.
Ismail MH, Molan AL, Abbas SK. Serological levels of cytokines in irritable bowel syndrome (IBS) patients and non-IBS subjects with and without Blastocystis spp. infection. Ann Parasitol. 2022;68:77–85.PubMed
40.
Nagel R, Traub RJ, Kwan MM, Bielefeldt-Ohmann H. Blastocystis specific serum immunoglobulin in patients with irritable bowel syndrome (IBS) versus healthy controls. Parasit Vectors. 2015;8:453.PubMedPubMedCentralCrossRef
41.
Chen H, Ou R, Tang N, Su W, Yang R, Yu X, Zhang G, Jiao J, Zhou X. Alternation of the gut microbiota in irritable bowel syndrome: an integrated analysis based on multicenter amplicon sequencing data. J Transl Med. 2023;21:117.PubMedPubMedCentralCrossRef
42.
Lee SM, Kim N, Yoon H, Kim YS, Choi SI, Park JH, Lee DH. Compositional and functional changes in the gut microbiota in irritable bowel syndrome patients. Gut Liver. 2021;15:253–61.PubMedCrossRef
43.
Lopetuso LR, Petito V, Graziani C, Schiavoni E, Paroni Sterbini F, Poscia A, Gaetani E, Franceschi F, Cammarota G, Sanguinetti M, et al. Gut microbiota in health, diverticular disease, irritable bowel syndrome, and inflammatory bowel diseases: time for microbial marker of gastrointestinal disorders. Dig Dis. 2018;36:56–65.PubMedCrossRef
44.
Barandouzi ZA, Lee J, Maas K, Starkweather AR, Cong XS. Altered gut microbiota in irritable bowel syndrome and its association with food components. J Pers Med. 2021;11:35.PubMedPubMedCentralCrossRef
45.
Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301:G799-807.PubMedPubMedCentralCrossRef
46.
Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The genus alistipes: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol. 2020;11:906.PubMedPubMedCentralCrossRef
47.
O’Riordan KJ, Collins MK, Moloney GM, Knox EG, Aburto MR, Fülling C, Morley SJ, Clarke G, Schellekens H, Cryan JF. Short chain fatty acids: microbial metabolites for gut-brain axis signalling. Mol Cell Endocrinol. 2022;546: 111572.PubMedCrossRef
48.
Oliphant K, Allen-Vercoe E. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. Microbiome. 2019;7:91.PubMedPubMedCentralCrossRef
49.
Jiang W, Wu J, Zhu S, Xin L, Yu C, Shen Z. The role of short chain fatty acids in irritable bowel syndrome. J Neurogastroenterol Motil. 2022;28:540–8.PubMedPubMedCentralCrossRef
50.
Sun Q, Jia Q, Song L, Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98: e14513.PubMedCrossRef
51.
Gargari G, Taverniti V, Gardana C, Cremon C, Canducci F, Pagano I, Barbaro MR, Bellacosa L, Castellazzi AM, Valsecchi C, et al. Fecal clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome. Environ Microbiol. 2018;20:3201–13.PubMedCrossRef
52.
Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019;16:461–78.PubMedCrossRef
53.
Deng L, Wojciech L, Png CW, Kioh DYQ, Gu Y, Aung TT, Malleret B, Chan ECY, Peng G, Zhang Y, et al. Colonization with two different Blastocystis subtypes in DSS-induced colitis mice is associated with strikingly different microbiome and pathological features. Theranostics. 2023;13:1165–79.PubMedPubMedCentralCrossRef
54.
Deng L, Wojciech L, Png CW, Koh EY, Aung TT, Kioh DYQ, Chan ECY, Malleret B, Zhang Y, Peng G, et al. Experimental colonization with Blastocystis ST4 is associated with protective immune responses and modulation of gut microbiome in a DSS-induced colitis mouse model. Cell Mol Life Sci. 2022;79:245.PubMedPubMedCentralCrossRef
55.
Mayneris-Perxachs J, Arnoriaga-Rodríguez M, Garre-Olmo J, Puig J, Ramos R, Trelis M, Burokas A, Coll C, Zapata-Tona C, Pedraza S, et al. Presence of Blastocystis in gut microbiota is associated with cognitive traits and decreased executive function. Isme J. 2022;16:2181–97.PubMedPubMedCentralCrossRef
56.
Schoultz I, Keita ÅV. The intestinal barrier and current techniques for the assessment of gut permeability. Cells. 1909;2020:9.
57.
Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intestin Res. 2015;13:11.CrossRef
58.
59.
Zhao X, Zeng H, Lei L, Tong X, Yang L, Yang Y, Li S, Zhou Y, Luo L, Huang J. Tight junctions and their regulation by non-coding RNAs. Int J Biol Sci. 2021;17:712.PubMedPubMedCentralCrossRef
60.
Xi M, Zhao P, Li F, Bao H, Ding S, Ji L, Yan J. MicroRNA-16 inhibits the TLR4/NF-κB pathway and maintains tight junction integrity in irritable bowel syndrome with diarrhea. J Biol Chem. 2022;298(11): 102461.PubMedPubMedCentralCrossRef
Metadata
Title
Profiling of the fecal microbiota and circulating microRNA-16 in IBS subjects with Blastocystis infection : a case–control study
Authors
Alireza Olyaiee
Abbas Yadegar
Elnaz Sadat Mirsamadi
Amir Sadeghi
Hamed Mirjalali
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01441-8

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Evaluation of Acinetobacter baumannii, Klebsiella pneumoniae, and Staphylococcus aureus respiratory tract superinfections among patients with COVID-19 at a tertiary-care hospital in Tehran, Iran

Review

Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent

Research

Bidirectional association between infectious gastroenteritis and inflammatory bowel disease: a population-based study

Research

Monocyte to high-density lipoprotein cholesterol ratio predicts poor outcomes in ischaemic heart failure patients combined with diabetes: a retrospective study

Review

Comparative efficacy of nine exercise methods on the prognosis in chronic kidney disease patients with hemodialysis: a systematic review and network meta-analysis

Research

Effectiveness of thyme honey in the management of xerostomia in geriatric patients with end-stage renal disease: a randomized controlled clinical trial with a biochemical assessment